Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Horizon Pharma and Mallinckrodt,the pharmaceuticals business of Covidien(COV), have signed a US co-promotion agreement for DUEXIS (ibuprofen and famotidine).
Subscribe to our email newsletter
Duexis is used for the relief of rheumatoid arthritis and osteoarthritis and to decrease the risk of developing upper gastrointestinal ulcers.
Mallinckrodt,will promote Duexis to targeted physicians and will receive compensation on reaching pre set targets.
As part of the agreement Mallinckrodt was granted by Horizonto the right co-promote Duexis in the US till 31 December 2014 .
Horizon Pharma president and chief executive officer Timothy P. Walbert said,"The Horizon sales force has performed well in the initial phase of the DUEXIS launch.As part of our continued commercial strategy, we believe the substantial promotional efforts of Mallinckrodt, along with increasing our own sales force with an additional 80 sales representatives will enable us to achieve critical mass in driving DUEXIS revenue."
The promotion of Duexis to physicians is expected to start in August 2012.
Covidien president Mark Trudeau said, "DUEXIS is a perfect complement to our existing portfolio of pain products," said,, pharmaceuticals.”